Replies to post #210472 on Biotech Values

[RioLobo]

>Dr. Gottlieb also said that savings on biosimilars—cheaper versions of complex biologic drugs—have been disappointing. Only two such drugs have launched in the U.S. so far, with limited uptake. <<

Does MNTA account for all two?

[DewDiligence]

Bullish for MNTA:

https://twitter.com/DewDiligence/status/877298032789909504